<DOC>
	<DOCNO>NCT01038011</DOCNO>
	<brief_summary>Randomized , control , double-blind , multicenter phase II study compare risedronate 35mg ( ActonelR 35mg weekly tablet ) versus placebo patient active ankylose spondylitis ( AS ) treat standard first second-line therapy . Primary efficacy endpoint : Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) . The time schedule perform BASDAI screening , upon inclusion ( T0 ) , 3 , 6 12 month time premature withdrawal case drop-out . secondary endpoint : - Clinical endpoint : The secondary efficacy measure follow : Bath Ankylosing Spondylitis Functional Index ( BASFI ) , Bath Ankylosing Spondylitis Metrology Index ( BASMI ) , ASAS ( Assessments Ankylosing Spondylitis ) Working Group core set domain , Spinal pain VAS , ESR , CRP percentage patient achieve 20 % great decrease parameter . These parameter determine T0 , T3 , T6 , T12 time premature withdrawal case drop-out . The spinal pain assess VAS also do screening . - DEXA : Dual Energy X-Ray-Absorptiometry ( DEXA ) measurement perform patient upon inclusion ( T0 ) end study ( T12 ) . - Biochemical marker : select biochemical marker bone metabolism measure T0 , T3 , T6 T12 time premature withdrawal case drop-out use commercially available kit . Bone formation assess serum bone-specific alkaline phosphatase ( BAP ) osteocalcin ( OC ) level use commercially available kit . Bone resorption assess serum C-terminal telopeptide type I collagen degradation ( Crosslaps R ) urinary N-terminal telopeptide type I collagen degradation ( Osteomark R ) . - Trial medicinal product</brief_summary>
	<brief_title>Efficacy Safety Risedronate ( Actonel ) , Third Generation Bisphosphonate Patients With Ankylosing Spondylitis : Phase 2 Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Inclusion criterion : •Male nonpregnant woman ( woman post menopausal , surgically sterile practice reliable method contraception may include ) age 20 year Meeting Modified New York diagnostic criterion AS ( Van der Linden S et al. , 1984 ) Symptoms active AS 6 month prior study entry Treated firstline therapy ( NSAIDs ) 6 month prior study entry Bath AS Disease Activity Index ( BASDAI ) score 4 great ( Garrett S et al , 1994 ) Spinal pain 4 great 10cm visual analogue scale despite maximum recommend tolerated dos NSAIDs give minimum 1 month prior study entry Exclusion criterion : •Endstage AS diffuse involvement spine ( complete ankylosis ) Intraarticular corticosteroid injection IV infusion methylprednisolone within past 2 month prior study entry . Patients IA corticosteroid injection sacroiliac joint within past 9 month prior study entry . Severe renal insufficiency : serum creatinine &gt; 25 % upper limit normal ( &gt; 177 umol/l ) Hypocalcemia Major surgery within past 3 month prior study entry plan ensue 12 month Orthopaedic surgery within last 12 month Severe infection comorbidities , active peptic ulcer disease Patients receive bisphosphonates past 12 month prior study entry patient know allergy bisphosphonates . Patients treat antiosteoporotic drug ( except : Calcium Vit . D ) past 12 month prior study entry . Patients unable remain upright position ( sit stand ) minimum 30 minute No write inform consent obtain inability collaborate study design .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>